Guselkumab Plus Golimumab Promising Combination For Ulcerative Colitis For patients with ulcerative colitis, combined induction treatment with guselkumab and golimumab was more effective at inducing a clinical response, clinical remission and endoscopic improvement after 12 weeks than either drug alone, according to a study presented at the 2022 annual meeting of the european crohn’s and colitis organisation. At week 50, 45 (63%) of 71 patients in the combination therapy group, 55 (76%) of 72 patients in the golimumab monotherapy group, and 46 (65%) of 71 patients in the guselkumab monotherapy group had reported at least one adverse event. the most common adverse events were ulcerative colitis, upper respiratory tract infection, headache, anaemia.
Guselkumab Plus Golimumab Shows Promise In Patients With Ulcerative Colitis In the study, infections occurred in 31% of the combination patients compared with 23.9% of the guselkumab patients and 31.9% of the golimumab patients, while the rate for serious infections was 2. Compare the efficacy and safety of guselkumab plus golimumab combination therapy with either monotherapy in patients with ulcerative colitis. methods. study design and participants. we did a randomised, double blind, controlled, phase 2, proof of concept trial (vega) at 54 sites, including hospitals, academic medical centres, and . research in. At week 38, 17 (24%) of 71 patients in the combination therapy group, four (6%) of 72 patients in the golimumab monotherapy group, and nine (13%) of 71 patients in the guselkumab monotherapy group had achieved endoscopic and histological remission—if this outcome is considered as full disease control in ulcerative colitis, comparable with. At week 38, 34 (48%) of 71 patients in the combination therapy group, 15 (21%) of 72 patients in the golimumab monotherapy group, and 22 (31%) of 71 patients in the guselkumab group had clinical remission according to the modified mayo score and 49 (69%) patients in the combination therapy group, 43 (60%) patients in the golimumab monotherapy.
Guselkumab Golimumab Combo Shows Promise For Ulcerative Colitis At week 38, 17 (24%) of 71 patients in the combination therapy group, four (6%) of 72 patients in the golimumab monotherapy group, and nine (13%) of 71 patients in the guselkumab monotherapy group had achieved endoscopic and histological remission—if this outcome is considered as full disease control in ulcerative colitis, comparable with. At week 38, 34 (48%) of 71 patients in the combination therapy group, 15 (21%) of 72 patients in the golimumab monotherapy group, and 22 (31%) of 71 patients in the guselkumab group had clinical remission according to the modified mayo score and 49 (69%) patients in the combination therapy group, 43 (60%) patients in the golimumab monotherapy. While this study was being conducted, guselkumab efficacy in uc was demonstrated in a phase 2a, proof of concept, double blind study of guselkumab monotherapy and combination therapy with the tnf α antagonist, golimumab, in patients with moderately to severely active uc who were naïve to tnf α antagonists and had an inadequate response intolerance to corticosteroids or immunosuppressants. Patients who received combination therapy with guselkumab and golimumab followed by maintenance treatment with guselkumab achieved clinical remission a (mmayo b) at week 38 (47.9 percent [34 71]) versus 31.0 percent (22 71) and 20.8 percent (15 72) of patients who received guselkumab or golimumab alone, respectively (nominal p=<0.05). 1.
Comments are closed.